<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35608808</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-501X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular diversity</Title>
          <ISOAbbreviation>Mol Divers</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Aryl-n-hexanamide linked enaminones of usnic acid as promising antimicrobial agents.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11030-022-10456-y</ELocationID>
        <Abstract>
          <AbstractText>Lichen secondary metabolites are well explored medicinal agents with diverse pharmacological properties. One of the important antibiotic lichen secondary metabolites is usnic acid. Its diverse medicinal profiles prompted us to explore it as a potential antitubercular molecule. Towards this direction, continuing our efforts on the discovery and development of new analogs with potent antitubercular properties we designed, synthesized, and evaluated a set of 37 usnic acid enaminone-coupled aryl-n-hexanamides (3-39). The study yielded a 3,4-dimethoxyphenyl compound (13, 5.3 µM) as the most active anti-TB molecule. The docking studies were performed on 7 different enzymes to better understand the binding modes, where it was observed that compound 13 bound strongly with glucose dehydrogenase (Gscore: - 9.03). Further antibacterial investigations revealed compound 2 with potent inhibition on Salmonella typhi and Bacillus subtilis (MIC 3 µM) and MIC values of 7 and 14 µM on Streptococcus mutans and Escherichia coli respectively. Compound 19 (3-F-5-CF<sub>3</sub>-phenyl) displayed encouraging antibacterial profiles against E. coli, S. typhi and S. mutans with MIC values of 10 µM respectively. Interestingly, compound 20 (2,6-difluorophenyl) also displayed good antibacterial activity against E. coli with an MIC value of 6 µM. These encouraging pharmacological results will help for better designing and developing usnic acid-based semi-synthetic derivatives as potential antimicrobial agents. A set of 37 new usnic acid enaminone-coupled aryl-n-hexanamides were synthesized and evaluated as potential antimicrobial agents. Compound 13 was identified as the most active antitubercular molecule. 13 was further docked against 7 different enzymes of tuberculosis. The molecule displayed maximum binding energy with the enzyme Glucose dehydrogenase (Gscore: - 9.03), indicating that these hexanamides possibly act by inhibiting the glucose metabolic pathway of the bacterium. Surprisingly, the intermediate hexanoic acid 2 was identified as potent antibacterial agent, acting on both gram-positive and gram-negative bacterial strains (3-14 μM). The active compounds may be subjected to structural iterations to develop further leads.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bangalore</LastName>
            <ForeName>Pavan Kumar</ForeName>
            <Initials>PK</Initials>
            <Identifier Source="ORCID">0000-0001-9637-8216</Identifier>
            <AffiliationInfo>
              <Affiliation>Fluoro and Agrochemicals Division, CSIR- Indian Institute of Chemical Technology, Hyderabad, Telangana, 500007, India. pavanb.1488@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, 201002, India. pavanb.1488@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Robert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, 14850, USA. pavanb.1488@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Pedapati</LastName>
            <ForeName>Ravi Kumar</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>Fluoro and Agrochemicals Division, CSIR- Indian Institute of Chemical Technology, Hyderabad, Telangana, 500007, India.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, 201002, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Pranathi</LastName>
            <ForeName>Abburi Naga</ForeName>
            <Initials>AN</Initials>
            <AffiliationInfo>
              <Affiliation>Fluoro and Agrochemicals Division, CSIR- Indian Institute of Chemical Technology, Hyderabad, Telangana, 500007, India.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, 201002, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Batchu</LastName>
            <ForeName>Uma Rajeswari</ForeName>
            <Initials>UR</Initials>
            <AffiliationInfo>
              <Affiliation>Applied Biology Division, CSIR- Indian Institute of Chemical Technology, Hyderabad, Telangana, 500007, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Misra</LastName>
            <ForeName>Sunil</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Applied Biology Division, CSIR- Indian Institute of Chemical Technology, Hyderabad, Telangana, 500007, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Estharala</LastName>
            <ForeName>Madhurekha</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Medicinal Chemistry and Antimycobacterial Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad, Telangana, 500078, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sriram</LastName>
            <ForeName>Dharmarajan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Medicinal Chemistry and Antimycobacterial Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad, Telangana, 500078, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kantevari</LastName>
            <ForeName>Srinivas</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Fluoro and Agrochemicals Division, CSIR- Indian Institute of Chemical Technology, Hyderabad, Telangana, 500007, India. kantevari@yahoo.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, 201002, India. kantevari@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Mol Divers</MedlineTA>
        <NlmUniqueID>9516534</NlmUniqueID>
        <ISSNLinking>1381-1991</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antimicrobial</Keyword>
        <Keyword MajorTopicYN="N">Antitubercular</Keyword>
        <Keyword MajorTopicYN="N">Molecular docking</Keyword>
        <Keyword MajorTopicYN="N">Secondary metabolite</Keyword>
        <Keyword MajorTopicYN="N">Usnic acid</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>11</Hour>
          <Minute>22</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35608808</ArticleId>
        <ArticleId IdType="doi">10.1007/s11030-022-10456-y</ArticleId>
        <ArticleId IdType="pii">10.1007/s11030-022-10456-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dyrkheeva N, Luzina O, Filimonov A, Zakharova O, Ilina E, Zakharenko A, Kuprushkin M, Nilov D, Gushchina I, Svedas V, Salakhutdinov N, Lavrik O (2019) Inhibitory effect of new semisynthetic usnic acid derivatives on human tyrosyl-DNA phosphodiesterase 1. Planta Med 85:103–111. https://doi.org/10.1055/a-0681-7069</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/a-0681-7069</ArticleId>
            <ArticleId IdType="pubmed">30142660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dyrkheeva NS, Filimonov AS, Luzina OA, Zakharenko AL, Ilina ES, Malakhova AA, Medvedev SP, Reynisson J, Volcho KP, Zakian SM, Salakhutdinov NF, Lavrik OI (2021) New hybrid compounds combining fragments of usnic acid and monoterpenoids for effective tyrosyl-DNA phosphodiesterase 1 inhibition. Biomolecules 11:973–975. https://doi.org/10.3390/biom11070973</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom11070973</ArticleId>
            <ArticleId IdType="pubmed">34356597</ArticleId>
            <ArticleId IdType="pmc">8301776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zakharenko AL, Luzina OA, Sokolov DN, Kaledin VI, Nikolin VP, Popova NA, Patel J, Zakharova OD, Chepanova AA, Zafar A, Reynisson J, Leung E, Leung IKH, Volcho KP, Salakhutdinov NF, Lavrik OI (2019) Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topotecan on in vivo tumor models. Eur J Med Chem 161:581–593. https://doi.org/10.1016/j.ejmech.2018.10.055</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2018.10.055</ArticleId>
            <ArticleId IdType="pubmed">30396105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filimonov AS, Chepanova AA, Luzina OA, Zakharenko AL, Zakharova OD, Ilina ES, Dyrkheeva NS, Kuprushkin MS, Kolotaev AV, Khachatryan DS, Patel J, Leung IKH, Chand R, Ayine-Tora DM, Reynisson J, Volcho KP, Salakhutdinov NF, Lavrik OI (2019) New hydrazinothiazole derivatives of usnic acid as potent Tdp1 inhibitor. Molecules 24:3711–3745. https://doi.org/10.3390/molecules24203711</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules24203711</ArticleId>
            <ArticleId IdType="pmc">6832265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luzina O, Filimonov A, Zakharenko A, Chepanova A, Zakharova O, Ilina E, Dyrkheeva N, Likhatskaya G, Salakhutdinov N, Lavrik O (2020) Usnic acid conjugates with monoterpenoids as potent tyrosyl-DNA phosphodiesterase 1 inhibitors. J Nat Prod 83:2320–2329. https://doi.org/10.1021/acs.jnatprod.9b01089</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jnatprod.9b01089</ArticleId>
            <ArticleId IdType="pubmed">32786885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyrczak-Felczykowska A, Narlawar R, Pawlik A, Guzow-Krzemińska B, Artymiuk D, Hać A, Ryś K, Rendina LM, Reekie TA, Herman-Antosiewicz A, Kassiou M (2019) Synthesis of usnic acid derivatives and evaluation of their antiproliferative activity against cancer cells. J Nat Prod 82:1768–1778. https://doi.org/10.1021/acs.jnatprod.8b00980</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jnatprod.8b00980</ArticleId>
            <ArticleId IdType="pubmed">31282672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S, Zang J, Huang M, Guan L, Xing K, Zhang J, Liu D, Zhao L (2019) Discovery of novel (+)-usnic acid derivatives as potential anti-leukemia agents with pan-pim kinases inhibitory activity. Bioorganic Chem 89:102971–102973. https://doi.org/10.1016/j.bioorg.2019.102971</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bioorg.2019.102971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samuelsen L, Hansen PE, Vang O (2020) Derivatives of usnic acid cause cytostatic effect in Caco-2 cells. Nat Prod Res. https://doi.org/10.1080/14786419.2020.1756796</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14786419.2020.1756796</ArticleId>
            <ArticleId IdType="pubmed">32352327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mallavadhani UV, Vanga NR, Rao KB, Jain N (2020) Synthesis and antiproliferative activity of novel (+)-usnic acid analogues. J Asian Nat Prod Res 22:562–577. https://doi.org/10.1080/10286020.2019.1603220</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10286020.2019.1603220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Victor K, Boris L, Athina G, Anthi P, Marija S, Marina K, Oliver R, Marina S (2018) Design, synthesis, and antimicrobial activity of usnic acid derivatives. Med Chem Commun 9:870–882. https://doi.org/10.1039/C8MD00076J</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C8MD00076J</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi C-J, Peng W, Zhao J-H, Yang H-L, Qu L-L, Wang C, Kong L-Y, Wang X-B (2020) Usnic acid derivatives as tau-aggregation and neuroinflammation inhibitors. Eur J Med Chem 187:111961. https://doi.org/10.1016/j.ejmech.2019.111961</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2019.111961</ArticleId>
            <ArticleId IdType="pubmed">31865017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fogel N (2015) Tuberculosis: a disease without boundaries. Tuberculosis 95:527–531. https://doi.org/10.1016/j.tube.2015.05.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tube.2015.05.017</ArticleId>
            <ArticleId IdType="pubmed">26198113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M (2016) Tuberculosis. Nat Rev Dis Primers 2:16706. https://doi.org/10.1038/nrdp.2016.76</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2016.76</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Global Tuberculosis Report (2020) Executive summary. World Health Organization https://apps.who.int/iris/bitstream/handle/10665/337538/9789240016095-eng.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>India TB Report (2021) Central TB division, India</Citation>
        </Reference>
        <Reference>
          <Citation>Griffin JD, Ellman L (1978) Epsilon-aminocaproic acid (EACA). Semin Thromb Hemost 5:27–40. https://doi.org/10.1055/s-0028-1087143</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0028-1087143</ArticleId>
            <ArticleId IdType="pubmed">568312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anandan SK, Ward JS, Brokx RD, Bray MR, Patel DV, Xiao XX (2005) Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorganic Med Chem Lett 15:1969–1972. https://doi.org/10.1016/j.bmcl.2005.02.075</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bmcl.2005.02.075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen B, Petukhov PA, Jung M, Velena A, Eliseeva E, Dritschilo A, Kozikowski AP (2005) Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. Bioorganic Med Chem Lett 15:1389–1392. https://doi.org/10.1016/j.bmcl.2005.01.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bmcl.2005.01.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C, Yin Q, Zhu W, Yang Y, Wang X, Qian X, Xu F (2011) Highly selective fluorescent probe for vicinal-dithiol-containing proteins and in situ imaging in living cells. Angew Chem Int Ed 50:7551–7556. https://doi.org/10.1002/anie.201101317</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.201101317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Granata G, Stracquadanio S, Consoli GML, Cafiso V, Stefani S, Geraci C (2019) Synthesis of a calix[4]arene derivative exposing multiple units of fucose and preliminary investigation as a potential broad-spectrum antibiofilm agent. Carbohydr Res 476:60–64. https://doi.org/10.1016/j.carres.2019.03.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.carres.2019.03.005</ArticleId>
            <ArticleId IdType="pubmed">30913401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Yang X, Fang H, Hou X (2019) Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors. Eur J Med Chem 181:111563. https://doi.org/10.1016/j.ejmech.2019.111563</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2019.111563</ArticleId>
            <ArticleId IdType="pubmed">31415980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Gao C, Zhao L, Yuan Z, Chen Y, Jiang Y (2018) Phthalimide conjugations for the degradation of oncogenic PI3K. Eur J Med Chem 151:237–247. https://doi.org/10.1016/j.ejmech.2018.03.066</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2018.03.066</ArticleId>
            <ArticleId IdType="pubmed">29625382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larcher A, Nocentini A, Supuran CT, Winum JY, van der Lee A, Vasseur JJ, Laurencin D, Smietana M (2019) Bis-benzoxaboroles: design synthesis and biological evaluation as carbonic anhydrase inhibitors. ACS Med Chem Lett 10:1205–1210. https://doi.org/10.1021/acsmedchemlett.9b00252</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsmedchemlett.9b00252</ArticleId>
            <ArticleId IdType="pubmed">31413806</ArticleId>
            <ArticleId IdType="pmc">6691558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stolfa DA, Marek M, Lancelot J, Hauser AT, Walter A, Leproult E, Melesina J, Rupmf T, Wurtz JM, Cavarelli J, Sippl W, Pierce RJ, Romier C, Jung M (2014) Molecular basis for the antiparasitic activity of a mercaptoacetamide derivative that inhibits histone deacetylase 8 (hdac8) from the human pathogen Schistosoma mansoni. J Mol Biol 426:3442–3453. https://doi.org/10.1016/j.jmb.2014.03.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jmb.2014.03.007</ArticleId>
            <ArticleId IdType="pubmed">24657767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paul S, Roy P, Sardar PS, Majhi A (2019) Design, synthesis, and biophysical studies of novel 1,2,3-triazole-based quinoline and coumarin compounds. ACS Omega 4:7213–7230. https://doi.org/10.1021/acsomega.9b00414</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsomega.9b00414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bangalore PK, Vagolu SK, Bollikanda RK, Veeragoni DK, Choudante PC, Misra S, Sriram D, Sridhar B, Kantevari S (2020) Usnic acid enaminone-coupled 1,2,3-triazoles as antibacterial and antitubercular agents. J Nat Prod 83:26–35. https://doi.org/10.1021/acs.jnatprod.9b00475</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jnatprod.9b00475</ArticleId>
            <ArticleId IdType="pubmed">31858800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marrero J, Trujillo C, Rhee KY, Ehrt S (2013) Glucose phosphorylation is required for mycobacterium tuberculosis persistence in mice. Plos Pathog 9:e1003116. https://doi.org/10.1371/journal.ppat.1003116</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1003116</ArticleId>
            <ArticleId IdType="pubmed">23326232</ArticleId>
            <ArticleId IdType="pmc">3542180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker PJ, Britton KL, Fisher M, Esclapez J, Pire C, Bonete MJ, Ferrer J, Rice DW (2009) Active site dynamics in the zinc-dependent medium chain alcohol dehydrogenase superfamily. PNAS 106:779–784</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0807529106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conway T (1992) The Entner–Doudoroff pathway: history, physiology, and molecular biology. FEMS Microbiol Rev 103:1–28. https://doi.org/10.1111/j.1574-6968.1992.tb05822.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1574-6968.1992.tb05822.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chikale RV, Barmade MA, Murumkar PR, Yadav MR (2018) Overview of the development of DprE1 inhibitors for combating the menace of tuberculosis. J Med Chem 61:8563–8593. https://doi.org/10.1021/acs.jmedchem.8b00281</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.8b00281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manina G, Pasca MR, Buroni S, De Rossi E, Riccardi G (2010) Decaprenylphosphoryl-β-D-ribose 2′-epimerase from Mycobacterium tuberculosis is a magic drug target. Curr Med Chem 17:3099–3108. https://doi.org/10.2174/092986710791959693</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/092986710791959693</ArticleId>
            <ArticleId IdType="pubmed">20629622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brecik M, Centarova I, Mukherjee R, Kolly GS, Huszar S, Bobovska A, Kilacskova E, Mokosova V, Svetlikova Z, Sarkan M, Neres J, Kordulakova J, Cole ST, Mikusova K (2015) DprE1 is a vulnerable tuberculosis drug target due to its cell wall localization. ACS Chem Biol 10:1631–1636. https://doi.org/10.1021/acschembio.5b00237</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.5b00237</ArticleId>
            <ArticleId IdType="pubmed">25906160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parikh SL, Xiao G, Tonge PJ (2000) Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39:7645–7650. https://doi.org/10.1021/bi0008940</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi0008940</ArticleId>
            <ArticleId IdType="pubmed">10869170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Xi P, Mead D, Crane DD, Musser JM, Barry CE III (1998) Inhibition of Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid. Science 280:1607–1610</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.280.5369.1607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basso LA, Zheng R, Musser JM, Jacobs WR Jr, Blanchard JS (1998) Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J Infect Dis 178:769–775. https://doi.org/10.1086/515362</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/515362</ArticleId>
            <ArticleId IdType="pubmed">9728546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgunova E, Meining W, Illarionov B, Haase I, Jin G, Bacher A, Cushman M, Fischer M, Ladenstein R (2005) Crystal structure of lumazine synthase from Mycobacterium tuberculosis as a target for rational drug design: binding mode of a new class of purinetrione inhibitors. Biochemistry 44:2746–2758. https://doi.org/10.1021/bi047848a</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi047848a</ArticleId>
            <ArticleId IdType="pubmed">15723519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng YS, Sacchettini JC (2016) Structural insights into Mycobacterium tuberculosis Rv2671 protein as a dihydrofolate reductase functional analogue contributing to para-aminosalicylic acid resistance. Biochemistry 55:1107–1119. https://doi.org/10.1021/acs.biochem.5b00993</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.biochem.5b00993</ArticleId>
            <ArticleId IdType="pubmed">26848874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long Q, Ji L, Wang H, Xie J (2010) Riboflavin biosynthetic and regulatory factors as potential novel anti-infective drug targets. Chem Biol Drug Des 75:339–347. https://doi.org/10.1111/j.1747-0285.2010.00946.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1747-0285.2010.00946.x</ArticleId>
            <ArticleId IdType="pubmed">20148904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aubry A, Fisher LM, Jarlier V, Cambau E (2006) First functional characterization of a singly expressed bacterial type II topoisomerase: The enzyme from Mycobacterium tuberculosis. Biochem Biophys Res Commun 348:158–165. https://doi.org/10.1016/j.bbrc.2006.07.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2006.07.017</ArticleId>
            <ArticleId IdType="pubmed">16876125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dighe SN, Collet TA (2020) Recent advances in DNA gyrase-targeted antimicrobial agents. Eur J Med Chem 199:112326–112338. https://doi.org/10.1016/j.ejmech.2020.112326</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2020.112326</ArticleId>
            <ArticleId IdType="pubmed">32460040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43:717–731. https://doi.org/10.1046/j.1365-2958.2002.02779.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2958.2002.02779.x</ArticleId>
            <ArticleId IdType="pubmed">11929527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tripathi SM, Ramachandran R (2006) Direct evidence for a glutamate switch necessary for substrate recognition: crystal structures of lysine ε-aminotransferase (Rv3290c) from Mycobacterium tuberculosis H37Rv. J Mol Biol 362:877–886. https://doi.org/10.1016/j.jmb.2006.08.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jmb.2006.08.019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanzawa T, Kato K, Girodat D, Ose T, Kumakura Y, Wieden HJ, Uchiumi T, Tanaka I, Yao M (2018) The C-terminal helix of ribosomal P stalk recognizes a hydrophobic groove of elongation factor 2 in a novel fashion. Nucleic Acids Res 46:3232–3244. https://doi.org/10.1093/nar/gky115</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gky115</ArticleId>
            <ArticleId IdType="pubmed">29471537</ArticleId>
            <ArticleId IdType="pmc">5887453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stewart JJP (2016) Stewart computational chemistry. Colorado Springs, CO, USA. http://OpenMOPAC.net</Citation>
        </Reference>
        <Reference>
          <Citation>Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchinson GR (2012) Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform 4:17</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1758-2946-4-17</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krishna VS, Zheng S, Rekha EM, Guddat LW, Sriram D (2019) Discovery and evaluation of novel Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors as therapeutic drug leads. J Comput Aided Mol Des 33:357–366. https://doi.org/10.1007/s10822-019-00184-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10822-019-00184-1</ArticleId>
            <ArticleId IdType="pubmed">30666485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Meerloo J, Kaspers GJL, Cloos J (2011) Cell sensitivity assays: the MTT assay. In: Cancer cell culture: methods and protocols, pp 237–245. https://doi.org/10.1007/978-1-61779-080-5_20</Citation>
        </Reference>
        <Reference>
          <Citation>Clinical and Laboratory Standards Institute (2008) Performance standards for antimicrobial susceptibility tests, Eighteen informational supplements M100-S18, CLSI</Citation>
        </Reference>
        <Reference>
          <Citation>Collins LA, Franzblau SG (1997) Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41:1004–1009. https://doi.org/10.1128/AAC.41.5.1004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.41.5.1004</ArticleId>
            <ArticleId IdType="pubmed">9145860</ArticleId>
            <ArticleId IdType="pmc">163841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schrodinger Release 2019-3: LigPrep, Schrodinger, LLC, New York, NY, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein, and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221–234. https://doi.org/10.1007/s10822-013-9644-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10822-013-9644-8</ArticleId>
            <ArticleId IdType="pubmed">23579614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177–6196. https://doi.org/10.1021/jm051256o</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm051256o</ArticleId>
            <ArticleId IdType="pubmed">17034125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shaw DE, Shelley M, Perry JK, Francis P, Shenki PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749. https://doi.org/10.1021/jm0306430</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm0306430</ArticleId>
            <ArticleId IdType="pubmed">15027865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750–1759. https://doi.org/10.1021/jm030644s</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm030644s</ArticleId>
            <ArticleId IdType="pubmed">15027866</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
